Navigation Links
Pacific Biosciences Acquires Single Molecule Sequencing Technology from LI-COR Biosciences
Date:5/27/2008

MENLO PARK, Calif. and LINCOLN, Neb., May 27 /PRNewswire/ -- Pacific Biosciences announced today that it has acquired "sequencing by incorporation" technology from LI-COR Biosciences of Lincoln Nebraska. Sequencing by incorporation generally identifies nucleotides in a DNA sequence based upon synthesis of a complementary DNA strand. The technology acquired from LI-COR broadens Pacific Biosciences' existing intellectual property related to the SMRT(TM), single molecule real time, sequencing method. Developed by Pacific Biosciences, SMRT technology is unique in the field of DNA Sequencing and offers the ultimate combination of speed, long reads, and low costs.

Included in the acquisition is a significant portfolio of key intellectual property developed under LI-COR's single molecule sequencing program, including a number of issued US and foreign patents as well as a number of pending US applications. LI-COR retained rights to its intellectual property for the sequencing enzymes that were designed for sequencing by polymerase synthesis, and LI-COR has an active program to out-license its enzymes. The acquisition also includes ongoing opportunities to collaborate with the LI-COR scientists on its sequencing enzymes.

"LI-COR's early developments in the field of sequencing by incorporation, as well as their comprehensive intellectual property portfolio surrounding those developments, provide a unique and attractive opportunity for us to combine our resources to build a strong foundation from which to ultimately deliver on the huge advantages of single molecule real time sequencing by synthesis," commented Hugh Martin, Pacific Biosciences' Chairman and CEO. "It has truly added to our breadth and depth in the field of long read DNA sequencing."

"We are quite pleased that Pacific Biosciences has acquired our early developments in single molecule DNA sequencing and will now shepherd the technology to market," said William Biggs LI-COR's President a
'/>"/>

SOURCE Pacific Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aton Pharma Announces Distribution Partnership in the Asia Pacific Region
2. BioMed Realty Trust Announces 140,000 Square Foot Lease With DayStar Technologies at Pacific Research Center
3. PacifiCare Capitulates to Latest Patient Revolt
4. Neptune Technologies expands into medicinal markets in Asia Pacific
5. Lucid Expands Support Internationally: Dr. Colin Stahel appointed Director for Asia Pacific Region
6. Verenium Corporation to Present at the Pacific Growth Equities 2007 Clean Technology & Industrial Growth Conference
7. PacificGMP Announces Agreement with BD Biosciences for Cell Banking and cGMP Antibody Manufacturing
8. Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
9. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
10. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
11. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...AI,Nov.24/PRNewswire-Asia/--ShanghaiBiolaxyannounc...)hasapprovedthe,investigationalnewdrugapplication(...insulinformulationtotreatdiabetes.ThisIND,approval.... , Diabetesisadisordercharacteristicofhighbl...betesoftenresultinseveremicro-and,macro-vasculardi...
(Date:11/24/2009)... The FBI recently approved the Promega ...ticipating in or generating DNA records for the Na... Madison, WI USA (PRWEB) -- The FBI recently appr... use by laboratories participating in, or generati...(NDIS). NDIS currently contains more than seven mi...
(Date:11/24/2009)...TURE:HTL , TORONTO,Nov.24/PRNewswire-FirstCal...pitalInc.,aleadingproviderofadvancedlasersystemsan...icmarkets,todayreportedoperationalandfinancialresu...2009Highlights,-Revenuewas$1.46millioncomparedwit...centcomparedwith66.1percentinQ3,2008,-Netlossreduc...
(Date:11/24/2009)...GO,Nov.24,2009/PRNewswire-FirstCall/--ArenaPharmac...ecompanyisscheduledtopresentatthePiperJaffray21stA...m.EasternTime(8:30a.m.PacificTime)attheNewYorkPala...dChiefExecutiveOfficer,isscheduledtoprovideanoverv...discoveryprograms. ,, Aliveaudiowebcastofthepre...
Breaking Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2
...O, Oct. 14 Nile Therapeutics,Inc. (Nasdaq: NLTX ...ter,open-label Phase 2a clinical study of CD-NP, a...ospitalized for acute heart failure., -- Statis...ry wedge pressure -- Statistically signific...on in right atrial pressure -- Trend toward incr...
...pport creation of market incentives and facilitate...O Ventures for Global,Health (BVGH) today announce...anded its support of the organization, so it can f... create new medicines for infectious,diseases of t...p BVGH build,the market case for biotechnology ind...
...ct. 14 Althea Technologies, Inc., a leading,provi...armaceutical,development and manufacturing, announ...fast growth awards, Deloitte LLP,s San Diego Techn...00 Fastest Growing Private Companies,for the fifth... is an,annual ranking of the 50 fastest growing te...
Other Biology Technology:Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure 2Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure 3Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure 4Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure 5BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World 2Althea Technologies Receives Fast Growth Honors: Deloitte Technology Fast 50 and San Diego Business Journal Fast 100 Awards for the Fifth Consecutive Year 2
(Date:11/23/2009)...e of day matters to forest trees dealing with drou...ch team led by Professor Malcolm Campbell, Univers...search and colleagues in the department of cell an...Capitalizing on their previous work to decode the ...ned how poplar trees use their 45,000 genes to res...
(Date:11/23/2009)...ipants gathered this week for the seventh annual N...ce. This year,s topic, "Synthetic Biology," brough...archers to explore the engineering, scientific, an...synthetic biology. , Bonnie L. Bassler, professo... this year,s conference chair, challenged the atte...
(Date:11/23/2009)...s "incontrovertible evidence" that the volcanic su...t 73,000 years ago deforested much of central Indi...s report. , The volcano ejected an estimated 800...ing a crater (now the world,s largest volcanic lak...ide. Ash from the event has been found in India, t...
Breaking Biology News(10 mins):Time of day matters to thirsty trees, U of T researcher discovers 2Synthetic biology offers new opportunities for interdisciplinary collaboration 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Bausch 26 Lomb Vision Care Strengthens Its Commitment to ReNu 28R 29 Brand and the Eye Care Community 50159 1Bausch 26 Lomb Vision Care Strengthens Its Commitment to ReNu 28R 29 Brand and the Eye Care Community 50159 2Bausch 26 Lomb Vision Care Strengthens Its Commitment to ReNu 28R 29 Brand and the Eye Care Community 50159 3Positive CHMP Opinion for JAVLOR 28R 29 in Metastatic Treatment of Bladder Cancer After Failure of a Prior Platinum Containing Regimen 50155 1Positive CHMP Opinion for JAVLOR 28R 29 in Metastatic Treatment of Bladder Cancer After Failure of a Prior Platinum Containing Regimen 50155 2Positive CHMP Opinion for JAVLOR 28R 29 in Metastatic Treatment of Bladder Cancer After Failure of a Prior Platinum Containing Regimen 50155 3RainEarth Obtains Patent Approvals for Its Core Technology 50153 1RainEarth Obtains Patent Approvals for Its Core Technology 50153 2RainEarth Obtains Patent Approvals for Its Core Technology 50153 3
...ornia,s Viterbi School of Engineering have success...onic Transmission Tomography" (HUTT) system that o...o those produced by existing commercial X-ray, ult...essor of biomedical engineering at the Viterbi Sch...in San Diego at the 28th International Acoustical ...
...iversity of Melbourne, Australia, has conducted th...volution of one of nature,s most sophisticated bio...the March issue of the journal Genome Research. , ...amily Colubroidea, evolved glands for the storage ...million years ago. Since that time, various prey-i...
...tes stem from bat bites, far more people are treat...e list of most often reported rabid mammal. Contro...he spatial dynamics of the disease - where new out... In a new study reported in the freely-available o...ply a mathematical model to predict the likely spr...
Other Biology News:A probe, not an echo 2A probe, not an echo 3A probe, not an echo 4Venom doc tracks down snake bioweapons 2Rabies spread speeds up 2
Goat Anti-Human ROR1 Polyclonal Antibody, Unconjugated from R&D Systems
Mouse Anti-Human Rad1 Monoclonal Antibody, Unconjugated, Clone 33 from R&D Systems
Sheep Growth Hormone from Cell Sciences
Rat Anti-Mouse Semaphorin 6B Monoclonal Antibody, Unconjugated, Clone 256537 from R&D Systems
Biology Products: